Gonzalo Monge, Matías Otto-Yáñez, Nicole Norambuena, V. Martinez, Daniela Retamales, R. Torres-Castro
{"title":"Safety of Hyperbaric Oxygenation Treatment and Evaluation of Associated Clinical Parameters: A Single-Institutional Prospective Cohort Study","authors":"Gonzalo Monge, Matías Otto-Yáñez, Nicole Norambuena, V. Martinez, Daniela Retamales, R. Torres-Castro","doi":"10.21106/ijtmrph.430","DOIUrl":"https://doi.org/10.21106/ijtmrph.430","url":null,"abstract":"Background and Objective: Adverse events (AEs) associated with hyperbaric oxygen therapy (HBOT) are uncommon and typically not serious, being the most frequent otic/sinus barotrauma. The objective of this study is to analyze the safety of the HBOT at 1.45 atmosphere absolute (ATA) and compare it with reportsat the same and higher pressures of treatment.\u0000AE per session was 7.1% for total AE and 4.1% for overall barotrauma. AE was reported in 28.3% of patients (n=49), with barotrauma and non-barotrauma AE in 20.3% (n=35) and 8.1% (n=14). All barotrauma was recorded as subjective (100% of ear ache without eardrum damage, Teed scale=0). The frequency of total AE obtained in our study was statistically higher for 1.5, 2, and >2 ATA. Non-barotrauma AE was also higher; the frequency of total AE obtained in our study was statistically significant for 1.5, 2, and >2 ATA but objective barotrauma was not present, and it was significantly lower than previously reported (p < 0.001). A very slow rate of pressurizations (below 1 psi/min) was associated with ear pain (OR=3.32; 95 CI%, 1.32-8.35; p < 0.001). The AEs reported in this safety surveillance prospective study are minor, and no objective barotrauma was reported. HBOT at 1.45 ATA is a safe treatment, that can be performed with a portable light and a less expensive hyperbaric chamber.\u0000Methods: A total of 175 patients (68 male, 107 female) were included in this prospective study. All patients were treated with HBOT at our facility from December 2019 to August 2021. For the comparative analysis, reports from studies published from 2012 to 2021 in MEDLINE EMBASE, BIREME, Lilacs, Scielo, and the Cochrane library were used. Binary variables are described in percentages with a 95% confidence interval (95% CI). Inferential analysis was performed using a bivariate analysis by calculating odds ratio (OR) with 95% confidence intervals. Statistical analyses and sample size calculations were performed with Stata version 13.0 (College Station, TX, USA).\u0000Results: In this study, the AE per session was 7.1% for total AE and 4.1% for overall barotrauma. AE was reported in 28.3% of patients (n=49), with barotrauma and non-barotrauma AE in 20.3% (n=35) and 8.1% (n=14), respectively. All barotrauma was recorded as subjective (100% of ear ache without eardrum damage, Teed scale=0). The frequency of total AE obtained in our study was statistically higher for 1.5, 2, and >2 ATA. Non-barotrauma AE was also higher, but objective barotrauma was not present and was significantly lower than previously reported (p <0.001). A very slow rate of pressurizations (below 1psi/minute) was associated with ear pain (OR = 3.32; 95% CI, 1.32-8.35; p <0.001).\u0000Conclusion and Implications for Translation: In this study, the AE reported in this prospective safety surveillance study are minor, and no objective barotrauma was reported. The HBOT at 1.45 ATA is a safe treatment that can be performed with a portable lighter and a less expensive hyperbar","PeriodicalId":93768,"journal":{"name":"International journal of translational medical research and public health","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43496242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Building Trust: Strategies for Recruiting Underrepresented Populations in Research during the COVID-19 Pandemic.","authors":"Leah K Claus, Sara S Jarvis","doi":"10.21106/ijtmrph.446","DOIUrl":"https://doi.org/10.21106/ijtmrph.446","url":null,"abstract":"<p><p>The COVID-19 pandemic disproportionately affected racial and ethnic populations within the United States, creating a distinct set of circumstances that exacerbated barriers to research participation for underrepresented communities. This article aims to provide a rationale that validates the impact of the COVID-19 pandemic on these groups and suggests strategies for participant recruitment while sharing lessons learned from our own laboratory. By understanding the barriers that limit the recruitment of intended populations, researchers can implement culturally sensitive strategies and work towards a more inclusive body of literature with improved participation from underrepresented racial and ethnic populations.</p>","PeriodicalId":93768,"journal":{"name":"International journal of translational medical research and public health","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41167849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lucrece Marcelline Delicat Loembet, A. Mabiala, U. Bisvigou, Eveline Avoune, Solange Bongo, André N’Tchoreret, Arnaud Kouoyo, A. Ondo, A. Dokekias, J. Koko, S. Ategbo
{"title":"Diagnosis of Sickle Cell Disease in Gabon Using Sickle SCAN®: A Point-of-Care Blood Test","authors":"Lucrece Marcelline Delicat Loembet, A. Mabiala, U. Bisvigou, Eveline Avoune, Solange Bongo, André N’Tchoreret, Arnaud Kouoyo, A. Ondo, A. Dokekias, J. Koko, S. Ategbo","doi":"10.21106/ijtmrph.315","DOIUrl":"https://doi.org/10.21106/ijtmrph.315","url":null,"abstract":"Background: Sickle cell disease (SCD) is the world’s most common genetic blood disorder. Most infant deaths from SCD occur in sub-Saharan Africa, and the mortality rate is exceptionally high in Gabon in Central Africa. In Gabon, there are limited resources for early and accurate detection of sickle cell or trait conditions. Most affected individuals reside in low-resource areas where access to diagnostic testing is often very limited. The most commonly used diagnostic methods require trained staff, adequate infrastructure, electric power, and enough time to perform the analysis. These requirements do not currently allow mass screening to be performed in remote areas of Gabon. The purpose of this pilot study is to develop a standardized screening procedure for SCD in order to determine its prevalence in the southeast area of Gabon by using a rapid and reliable test that does not require significant resources, such as the Sickle SCAN® device.\u0000Methods: The accuracy of the Sickle SCAN® device was assessed based on testing 272 blood samples. The exact hemoglobin was identified in 100% of the samples. The test comprises three proprietary indicators that detect the presence of hemoglobin A, S, and C, thus allowing the user to rapidly distinguish between normal (HbAA, N=142), carrier (HbAS, N=41), and sickle cell disease (HbSS, N=88; HbSC, N=1) samples. Hemoglobin variants (S and C) were confirmed by capillary electrophoresis (MinicapR; Sebia). The sensitivity and specificity were calculated for each phenotype.\u0000Results: The Sickle SCAN® test analysis revealed the following normal and abnormal phenotypes, including sickle cell trait (HbAS=14,71%) and SCD [HbSS (32.35%) and HbSC (0,74)]. There are no false positives in Sickle SCAN® result for the presence of hemoglobin variant, compared to gold standard approaches to capillary electrophoresis. The estimated sensitivity of the Sickle Scan® test was 92.2%, 100%, and 100% for HbSS, HbAS, and HbSC, respectively. The specificity exceeded 88.23% for all phenotypes (HbSS, HbAS, and HbSC).\u0000Conclusion and Implications for Translation: The Sickle Scan® device was found to be reliable with a sensitivity of 92.2%, 100%, and 100% for HbSS, HbAS, and HbSC, respectively. The specificity exceeded 88% for all phenotypes.\u0000 \u0000RESUME\u0000Contexte: La drépanocytose est la maladie génétique du sang la plus répandue dans le monde. La plupart des décès de nourrissons dus à la drépanocytose surviennent en Afrique subsaharienne, et le taux de mortalité est particulièrement élevé au Gabon, en Afrique Centrale. Au Gabon, les ressources pour la détection précoce et précise de l’anémie falciforme ou du trait de l’anémie sont limitées. La plupart des personnes touchées résident dans des zones à faibles ressources où l’accès aux tests de diagnostic est souvent très limité. Les méthodes de diagnostic les plus couramment utilisées nécessitent un personnel formé, une infrastructure adéquate, de l’électricité et suffisamment de temps pour effectu","PeriodicalId":93768,"journal":{"name":"International journal of translational medical research and public health","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42617041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}